Interstitial lung disease including idiopathic pulmonary fibrosis Respiratory Interstitial lung disease including idiopathic pulmonary fibrosis
Conditions
Interventions
Participants are randomly allocated to one of two groups using a computer generated randomisation list.
Control Group (Group 1): Those in the first group receive a tailored rehabilitation programme f
Sponsors
Newcastle University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Working diagnosis of IPF or ILD made by a multi-disciplinary team 2. MRC dyspnoea score is between 2 to 5 3. Aged 40 or older
Exclusion criteria
Exclusion criteria: 1. Uncontrolled hypertension 2. Uncontrolled cardiac disease 3. Inability to perform exercises, for example: neuromuscular or orthopeaedic diseases 4. Inability to follow instructions, for example: learning difficulty 5. Inability to commit to transportation to the exercise facility during the study 6. Participation in pulmonary rehabilitation in the last 6 months 7. History of syncope on exertion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Number of people recruited is measured using the study records at baseline and eight weeks 2. Number of people who complete the study is measured using study records at baseline and eight weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Inspiratory muscle pressure (IMP) is measured using the POWERbreathe KH2 machine at baseline and eight weeks 2. Palliative care needs (patients' physical symptoms, psychological, emotional and spiritual, and information and support needs) is measured using the palliative care outcome scale (IPOS) at week one, two, three, four, five, six, seven and eight. 3. Breathlessness and other symptoms of IPF are measured using the K-Bild questionnaire at baseline and eight weeks 4. Quadriceps, elbow, and shoulder muscles strength is measured using microFET device at baseline and eight weeks 5. Anxiety and depression is measured using the Hospital anxiety and Depression Scale at baseline and eight weeks 6. Biomarkers are measured using blood samples at baseline and eight weeks 7. Fatigue is measured using the Fatigue Severity Scale at baseline and eight weeks 8. Lung volumes and capacities are measured using spirometry at baseline and eight weeks 9. Lung diffusion capacity is measured using the diffusion capacity to carbon monoxide at baseline and eight weeks 10. Walking distance assessment is measured using the six-minute walk test at baseline and eight weeks | — |
Countries
England, United Kingdom
Outcome results
None listed